REVIEW ARTICLE

Proliferative verrucous leukoplakia: diagnosis, management and current advances

Diogo Lenzi Capella\textsuperscript{a}, Jussara Maria Gonçalves\textsuperscript{a}, Adelino António Artur Abrantes\textsuperscript{a}, Liliane Janete Grando\textsuperscript{b}, Filipe Ivan Daniel\textsuperscript{b,\ast}

\textsuperscript{a} Universidade Federal de Santa Catarina (UFSC), Programa de Pós-graduação em Odontologia, Florianópolis, SC, Brazil
\textsuperscript{b} Universidade Federal de Santa Catarina (UFSC), Departamento de Patologia, Florianópolis, SC, Brazil

Received 24 February 2016; accepted 8 December 2016
Available online 24 January 2017

KEYWORDS
Leukoplakia oral; Leukoplakia; Proliferative verrucous leukoplakia; Oral cancer; Squamous cell carcinoma; Head and neck cancer

Abstract

Introduction: Proliferative verrucous leukoplakia is a multifocal and progressive lesion of the oral mucosa, with unknown etiology, and commonly resistant to all therapy attempts with frequent recurrences. It is characterized by a high rate of oral squamous cell carcinoma and verrucous carcinoma transformations.

Objective: To analyze the studies about Proliferative verrucous leukoplakia and develop a concise update.

Methods: A Pubmed search identifying studies (laboratory research, case series and reviews of literature) that examined patients with Proliferative verrucous leukoplakia was realized.

Results: There are not enough studies about Proliferative verrucous leukoplakia in the literature. The few found studies not present a consensus about its etiology and diagnosis criteria. Although several treatment strategies have been proposed, most of them still show a high recurrence rate.

Conclusion: More research about Proliferative verrucous leukoplakia is necessary to understand and treat this disease.

© 2017 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

\textsuperscript{\ast} Please cite this article as: Capella DL, Gonçalves JM, Abrantes AA, Grando LJ, Daniel FI. Proliferative verrucous leukoplakia: diagnosis, management and current advances. Braz J Otorhinolaryngol. 2017;83:585–93.

\textsuperscript{*} Corresponding author.
E-mails: filipe.daniel@ufsc.br, filipedaniel06@gmail.com (F.I. Daniel).

Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.

http://dx.doi.org/10.1016/j.bjorl.2016.12.005
1808-8694/© 2017 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Leucoplasia verrucosa proliferativa: diagnóstico, conduta e avanços atuais

Resumo
Introduction: Leucoplasia verrucosa proliferativa (LVP) é uma lesão multifocal e progressiva da mucosa oral, com etiologia desconhecida e comumente resistente a todas as tentativas terapêuticas, com recorrências frequentes. É caracterizada por uma alta taxa de transformação em carcinoma de células escamosas e carcinoma verrucoso da cavidade oral.

Objetivo: Analisar os estudos sobre LVP e elaborar uma atualização resumida.

Método: Foi realizada uma pesquisa na base de dados Pubmed identificando estudos (pesquisas laboratoriais, séries de casos e revisões de literatura) que avaliaram pacientes com LVP.

Resultados e discussão: Não há estudos suficientes sobre LVP na literatura. Os poucos estudos encontrados não apresentam consenso quanto aos critérios de etiologia e diagnóstico. Embora várias estratégias de tratamento tenham sido propostas, a maioria ainda apresenta alta taxa de recorrência.

Conclusão: Mais pesquisas sobre LVP são necessárias para entender e tratar esta doença.

© 2017 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob uma licença CC BY (http://creativecommons.org/licenses/by/4.0/).

PALAVRAS-CHAVE
Leucoplasia oral;
Leucoplasia;
Leucoplasia verrucosa proliferativa;
Câncer oral;
Carcinoma, Célula escamosa;
Câncer de cabeça e pescoço

Introduction

Proliferative verrucous leukoplakia (PVL) is a very aggressive and rare form of oral leukoplakia (OL) with high morbidity.¹ The first description has been made by Hansen et al. (1985) as a distinct form of OL which develops initially as a white plaque that eventually becomes multifocal slow-growing lesions resistant to all therapeutic procedures, including surgery, with a high recurrence rate and an oral cancer transformation trend.² With the introduction of the term PVL, the previously used term “oral florid papillomatosis” has disappeared from the literature.¹ Actually, the World Health Organization (WHO) (2005) described PVL as “a rare but distinctive high-risk clinical form of oral precursor lesions”.⁴ Several studies have examined PVL characteristics and its propensity to develop into oral carcinoma.³ Thirty years after its discovery, it is still a challenging disease with no confirmed etiology and efficient treatment. Although there are published papers about PVL diagnosis criteria, they may be imprecise in detecting early disease presentations, either for clinical or histopathological view. The objective of this paper is to analyze the PVL literature and to develop a concise update.

Results and discussion

Etiology

Hansen et al. (1985) described PVL as a disease with unclear etiology, but typically associated with tobacco use.² However, the role of tobacco in PVL lesions is unknown since these lesions are seen in smokers and nonsmokers (Table 1).¹,²,⁵-¹⁵ Several studies evaluated alcohol use by PVL patients, but the relation between them was not established (Table 1).¹,⁹,¹¹,¹³

In recent years, it has been hypothesized that human papillomavirus (HPV) may influence both potentially and already established oral malignant lesions.¹⁶ Although the association between oral squamous cell carcinoma (OSCC) and HPV is already mentioned, its influence on PVL cases is not confirmed yet.¹⁷ Over the last decades, some studies reported different and contradictory frequencies of HPV DNA detection in PVL (Table 2).¹,⁷,¹⁰,¹⁸,¹⁹

About other possible etiologies, there are few studies with PVL that tried to identify the presence of Candida albicans. Silverman et al. (1997) reported 19 of 38 specimens with C. albicans positivity, but without correlation between the fungal infection and PVL occurrence or progression to carcinoma, characterizing it as a probable secondary infection.⁶ Similarly, Hansen et al. (1985) observed that 12 of 30 patients were positive for C. albicans.² Concerning to Epstein Barr Virus (EBV), Bagan et al. (2008) was the only one to detect EBV in a PVL group (60% of 6 patients).²⁰ Therefore, none of these studies have yet established the exact role of microbiological agents in PVL pathogenesis.

Review methods

A PubMed search using the term “Proliferative Verrucous Leukoplakia” was made from 1985 to 2015 (30 years). Additional papers were included based upon the original literature search and references in the selected papers. Papers concerning laboratory research, case series, as well as reviews of literature were also included.
Table 1  Studies of PVL cases series.

<table>
<thead>
<tr>
<th>Authors</th>
<th>No. of cases</th>
<th>Age (Mean, range)</th>
<th>Sex (M/F)</th>
<th>Tobacco use</th>
<th>Alcohol use</th>
<th>Follow-up (years, mean)</th>
<th>Malignant transf.</th>
<th>Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hansen et al. (1985)</td>
<td>30</td>
<td>65.9 (27-90)</td>
<td>6/24</td>
<td>18</td>
<td>Non-reported</td>
<td>6.1h,b,d</td>
<td>VC</td>
<td>90%</td>
</tr>
<tr>
<td>Kahn et al. (1994)</td>
<td>4</td>
<td>72.25 (75-79)</td>
<td>2/2</td>
<td>2</td>
<td>0</td>
<td>4h,b,c</td>
<td>VC</td>
<td>75%</td>
</tr>
<tr>
<td>Zakrzewska et al. (1996)</td>
<td>10</td>
<td>63.6 (42-81)</td>
<td>5/5</td>
<td>7</td>
<td>Non-reported</td>
<td>7.5b,c,d</td>
<td>VC</td>
<td>90%</td>
</tr>
<tr>
<td>Silverman and Gorsky (1997)</td>
<td>54</td>
<td>62 (22-89)</td>
<td>11/43</td>
<td>17</td>
<td>Non-reported</td>
<td>11.6b,c,d</td>
<td>OSCC</td>
<td>85%</td>
</tr>
<tr>
<td>Fettig et al. (2000)</td>
<td>10</td>
<td>65.2 (51-82)</td>
<td>6/4</td>
<td>3</td>
<td>Non-reported</td>
<td>5b,c</td>
<td>VC</td>
<td>100%</td>
</tr>
<tr>
<td>Bagan et al. (2003)</td>
<td>30</td>
<td>70.97 (84-58)</td>
<td>6/24</td>
<td>7</td>
<td>Non-reported</td>
<td>4.7b,c</td>
<td>OSCC</td>
<td>86.7%</td>
</tr>
<tr>
<td>Ghazali et al. (2003)</td>
<td>9</td>
<td>61.6 (24-76)</td>
<td>2/7</td>
<td>4</td>
<td>1</td>
<td>4.7b,c</td>
<td>VC</td>
<td>-</td>
</tr>
<tr>
<td>Campisi et al. (2004)</td>
<td>58</td>
<td>66.5 (54-79)</td>
<td>22/36</td>
<td>17</td>
<td>Non-reported</td>
<td>10</td>
<td>OSCC</td>
<td>Non-reported</td>
</tr>
<tr>
<td>Bagan et al. (2007)</td>
<td>13</td>
<td>68.3 (45-86)</td>
<td>0/13</td>
<td>3</td>
<td>Non-reported</td>
<td>1</td>
<td>Non-reported</td>
<td>VC</td>
</tr>
<tr>
<td>Klanrit et al. (2007)</td>
<td>6</td>
<td>65.8 (56-81)</td>
<td>1/5</td>
<td>1</td>
<td>Non-reported</td>
<td>6c</td>
<td>VC</td>
<td>-</td>
</tr>
<tr>
<td>Morton et al. (2007)</td>
<td>3</td>
<td>80 (73-89)</td>
<td>1/2</td>
<td>1</td>
<td>Non-reported</td>
<td>3.7c</td>
<td>VC</td>
<td>66.6%</td>
</tr>
<tr>
<td>Gandelofo et al. (2009)</td>
<td>47</td>
<td>65.9 (40-86)</td>
<td>10/37</td>
<td>17</td>
<td>Non-reported</td>
<td>12</td>
<td>HPV18</td>
<td>Non-reported</td>
</tr>
<tr>
<td>Bagan et al. (2011)</td>
<td>55</td>
<td>61.69 (73-50)</td>
<td>19/36</td>
<td>20</td>
<td>Non-reported</td>
<td>7.53b,c</td>
<td>HPV18</td>
<td>85%</td>
</tr>
<tr>
<td>Gouvêa et al. (2013)</td>
<td>21</td>
<td>65.5 (79-52)</td>
<td>3/18</td>
<td>11</td>
<td>Non-reported</td>
<td>7.38b,c</td>
<td>OSCC</td>
<td>Non-reported</td>
</tr>
</tbody>
</table>
| VC, verrucous carcinoma; OSCC, oral squamous cell carcinoma.  
  a Follow up until the cure.  
  b Follow up during proliferative verrucous leukoplakia progress.  
  c Follow up until malignant transformation.  
  d Follow up until death. 

Table 2  Studies about HPV presence in PVL.

<table>
<thead>
<tr>
<th>Author</th>
<th>No. of cases</th>
<th>HPV positive</th>
<th>HPV types</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palefsky et al. (1995)</td>
<td>9</td>
<td>8 (88.8%)</td>
<td>HPV 16 (n = 7; 77.7%)</td>
</tr>
<tr>
<td>Gopalakrishnan et al. (1997)</td>
<td>10</td>
<td>2 (20%)</td>
<td>HPV 16 (n = 1; 11.1%)</td>
</tr>
<tr>
<td>Fettig et al. (2000)</td>
<td>10</td>
<td>0</td>
<td>HPV 16 (n = 1; 10%)</td>
</tr>
<tr>
<td>Campisi et al. (2004)</td>
<td>58</td>
<td>14</td>
<td>HPV18 (n = 10; 17.24%)</td>
</tr>
<tr>
<td>Bagan et al. (2007)</td>
<td>13</td>
<td>0</td>
<td>HPV 16 (n = 4; 6.8%)</td>
</tr>
</tbody>
</table>
| HPV, human papillomavirus; PVL, proliferative verrucous leukoplakia. 

Epidemiological and clinical characteristics

In the studies evaluated in this paper, PVL occurred predominantly in women, with a 2.72:1 (female/male) rate, and a mean age of 66.8 years (Table 1).<sup>1,2,5-15,21</sup> The most affected sites were gingiva,<sup>8-10,12,14,15</sup> buccal mucosa,<sup>2,5,6</sup> and alveolar ridge,<sup>11,13</sup> while the tongue was less involved.<sup>21</sup>

Zakrzewska et al. (1996) observed that initial PVL clinical features included small whitish and well-defined signs of non-homogeneous leukoplakic lesions with speckled pattern.<sup>5</sup> According to Ghazali et al. (2003), PVL...
initially presents as unifocal, homogeneous, slow and persistent growth lesion. At this stage, it is extremely difficult, if not impossible, to distinguish it from oral leukoplakia. PVL has one or more areas of homogeneous leukoplakia, which grows slowly and persistently, and tends to become multifocal with exophytic, verrucous, or eryhematos areas. After a long period, commonly six years, the evolution to carcinoma occurs. Areas that are eryhematos, verrucous or have papillary surface are characteristic of malignant transformation, and so these areas should have a histopathological confirmation (Fig. 1).

Figure 1  (A) Proliferative verrucous leukoplakia (PVL) in the lower attached gingival, vestibular sulcus and gradually extended along left alveolar ridge. (B) PVL in the buccal mucosa with different clinical patterns: larger areas of homogeneous leukoplakias and spot areas of thickening of the keratinization and/verrucous surface. (C and D) PVL in ventral tongue and floor of mouth with exophytic appearance and focal area of granular pattern in both alveolar ridges. (E) Histopathological view showing acanthosis and hyperkeratosis with mild dysplasia. (F) Exophytic, hyperkeratotic lesion with prominent verruciform or papillary surface and acanthosis forming blunt projections into the lamina propria. (G) Hyperkeratosis, acanthosis, irregularity of the basal layer and some areas of epithelial atrophy. (H) Hyperkeratosis with droplet-shaped epithelial projections and intact lamina propria (HE, original magnification 40×).
Recently, a PVL subtype designated proliferative verrucous leukoplakia of the gingiva (PVLG) has been reported as involving exclusively free and attached gingiva. PVLG is characterized as a whitish plaque, unifocal, recurrent and progressive lesion. The course is also unpredictable and may undergo OSCC or verrucous carcinoma (VC) transformation.

As the evolution stages of different sites in multifocal lesions are not necessarily the same, patients should be monitored closely, with frequent and repetitive biopsies when there are changes in color, appearance or size, and when new lesions appear. Patients with whitish harmless appearance and recurrence episodes should also be followed up every six months. PVL may progress to VC or OSCC over time in spite of numerous treatment interventions, suggesting that PVL is associated with diffuse submicroscopic changes of the oral mucosa, sometimes described as "field cancerization". Therefore, PVL presents a high malignant transformation rate (Table 1).

**Histopathology**

Histopathological findings may show acanthosis and hyperkeratosis with an interface lymphocytic infiltrate within the superficial lamina propria. If the lesions continue to grow horizontally and vertically, there are histopathological changes that increase roughness of surface with verrucous aspect, and hyperplasia with or without dysplasia.

**Biomarkers**

Recent findings have indicated that carcinogenesis is a result of accumulated genetic and epigenetic alterations that may lead to chromosomal instability, in the form of numerical or structural aberrations, which might be detected as abnormal DNA content or aneuploidy. Ploidy analysis in PVL was performed in three different studies with a high prevalence. Khan et al. (1994) analyzed 4 PVL by flow cytometry and
found DNA aneuploid in all cases.\textsuperscript{15} Klanrit et al. (2007) analyzed 6 paraffin-embedded PVL samples and detected 4 (66.6\%) cases with abnormal ploidy status prior to malignant transformation.\textsuperscript{11} Gouvea et al. (2013) analyzed DNA of 20 patients with PVL and 19 (95\%) cases showed aneuploidy, with abnormal DNA observed even in the more indolent lesions.\textsuperscript{21}

Therefore, several studies have been conducted to determine whether improved expression levels of some molecular markers involved in different cellular pathways can be valuable indicators of clinical behavior.\textsuperscript{11} Gopalakrishnan et al. (1997) studied p53 expression in 10 samples and found minimal markup in normal oral mucosa, but positivity in 8 (80\%) of the cases of PVL, and in 7 (70\%) of the cases of OSCC.\textsuperscript{19} Fettig et al. (2000) identified p53 expression in 4 (40\%) of the 10 analyzed cases.\textsuperscript{7} Gouvea et al. (2013) showed p53 immunoreactivity in 14 (77.7\%) of the 18 cases.\textsuperscript{11} In the same study Ki-67 expression was similar to the one observed with p53 protein progression of epithelial dysplasia in PVL. Ki-67 is a nuclear protein associated with cellular proliferation with potential predictive biomarker in early stages of OSCC and can be used in addition to conventional tumor staging for optimal therapeutic management.\textsuperscript{11} Akrish et al. (2015) realized a retrospective review of 11 patients with PVL, 38 with carcinoma arising in patients with PVL (P-SCC) and 49 with conventional squamous cell carcinoma (C-SCC).\textsuperscript{20} Overexpression of p53 was more common in P-SCC, but without ki-67 or p16 overexpression. Krest et al. (2014) evaluated cell cycle regulatory genes in 20 PVL cases and detected deletion or mutation event involving both p16INK4a and p14ARF genes in 45\% of the cases.\textsuperscript{25}

### Diagnostic criteria

Hansen et al. (1985) determined that lesions diagnosed as PVL could have initially a homogeneous aspect, without dysplasia, followed by warty appearance of surface areas and multiple discrete or confluent lesions in single or multiple intra-oral sites.\textsuperscript{2}

According to Cerero-Lapiiedra et al. (2010), studies published on PVL followed the diagnostic criterion postulated by Hansen et al. (1985).\textsuperscript{2,23} It is a pioneering and comprehensive description, but still needs updates. Therefore, the same authors proposed the reformulation of the criteria by dividing them into major (five criteria) and minor (four criteria) (Table 3). To PVL diagnosis, patient should have one of the following combinations:

- Three major criteria (one of which must include the evolution of the histopathological lesions).
- Two major criteria (one of which must include the evolution of the histopathological lesions) + two minor criteria.

Bagan et al. (2011) believed that these criteria are useful only for those with clinical experience with PVL, but can be confusing for beginners.\textsuperscript{14} Corroborating with this observation, Carrard et al. (2013) suggested simplifying the diagnostic criteria by omitting the distinction between major and minor criteria. However, all four criteria should be met (Table 4).\textsuperscript{36}

### Treatment and recurrence

This literature review (Table 5) showed different treatments modalities. Surgery and laser ablation were the most used. Ten papers utilized surgery in 136 cases\textsuperscript{2,5,6,9,11,12,14,15} and seven papers used laser ablation in 64 cases.\textsuperscript{2,5,7,8,11,14,15} According to evaluated studies, with at least 30 patients, we found a recurrence mean rate of 85\% for all treatment modalities isolated or associated.\textsuperscript{12,4,8,13,14}

### Table 3 Proposal of major and minor diagnostic criteria for PVL recommended by Cerero-Lapiiedra et al. (2010).\textsuperscript{23} Adapted from Carrard et al.\textsuperscript{36}

<table>
<thead>
<tr>
<th>Major criteria</th>
<th>Minor criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Leukoplakia lesion with more than two different oral sites. It is frequently found in the gingiva, alveolar processes and palate.</td>
</tr>
<tr>
<td>B</td>
<td>The existence of a verrucous area.</td>
</tr>
<tr>
<td>C</td>
<td>Lesions that spread or engross during the disease development</td>
</tr>
<tr>
<td>D</td>
<td>There has been a recurrence in a previously treated area.</td>
</tr>
<tr>
<td>E</td>
<td>Can vary from simple epithelial hyperkeratosis to OSCC, whether in situ or infiltrating.</td>
</tr>
</tbody>
</table>

PVL, proliferative verrucous leukoplakia.

### Table 4 Modified diagnostic criteria for PVL recommended by Carrard et al. (2013).\textsuperscript{36} Adapted from Carrard et al.\textsuperscript{36}

1. Leukoplakia showing the presence of verrucous or wartlike areas, involving more than two oral subsites.
2. When adding all involved sites the minimum size should be at least three centimeters.
3. Well documented period of disease evolution of at least five years, characterized by spreading and enlarging and the occurrence of one or more recurrences in a previously treated area.
4. The realization of at least one biopsy (to rule out the presence of a VC or OSCC).

PVL, proliferative verrucous leukoplakia.
There are 2 descriptions about the association between surgery and laser ablation with no improvement.  

Zakrzewska et al. (1996) showed one patient with no recurrence at the laser-treated sites, but new lesions developed elsewhere. Bagan et al. (2003), after treating 24 patients (80%) with surgery and 18 (60%) with laser ablation, detected recurrence rate of 86.7% and recognized new lesions in 83.3%. Fettig et al. (2000) identified that both simple excision and laser excision were ineffective in eradicating lesions.  

Surgery, despite high recurrence rates, gives the possibility of dysplasia histologic grading and early detection of malignant transformation. Laser ablation should be indicated for lesions where the surgery would be contraindicated by lesion size or access difficulty. Development of new lesions in these patients is constant; thus, multiple interventions are always necessary.

Hansen et al. (1985) utilized radiation in 16 patients and chemotherapy in 6, with only one patient free of PVL at 6 years after treatment; therefore, they concluded that radiation therapy is not entirely satisfactory in a widespread disease such as PVL. In spite of these results, others papers reported the association between radiation and surgery to treat PVL, totaling 24 cases described in the literature. Silverman et al. (1997) reported that radiation was not effective in controlling PVL based on the lack of response of the cases treated with radiotherapy.

Zakrzewska et al. (1996) treated one patient with radiotherapy, but lesions continued to appear throughout the mouth. One patient also received a limited course of chemotherapy, but new lesions appeared, demonstrating the ineffectiveness of these treatment. Radiotherapy or chemotherapy did not show improvement in lesion recurrence, and showed severe side effects such as mucositis, infection, and salivary gland problems.

Extensive surgery such as resection was performed in only one case by Fettig et al. (2000). According to the authors, local block resection was required to prevent recurrences. In spite of this report, one case is not sufficient to confirm the potential of this therapy modality. In addition to its radical and debilitating characteristic, extensive resection is only acceptable when OSCC transformation with bone invasion is present.

Photodynamic therapy (PDT) associated to laser ablation would appear to offer slight improvement prognosis, because it makes treatment of multifocal areas possible with acceptable morbidity, but it did not prevent new lesions and until the moment there is only one study demonstrating its efficacy.

A preliminary study of Poveda-Roda et al. (2010) revealed that topical or systemic retinoic acid produces improvement in about one-third of all patients with PVL, but clinical worsening was recorded in another third of cases.
Besides, further studies are needed to assess the safety of these products, because frequent adverse effects can occur. The most frequent adverse effects were cheilitis, desquamation, pruritus, alopecia and rhinitis, which coincided with the well-known retinoid side effects. However, two of the patients suffered serious problems not described in the Summary of Product Characteristics of the medication used; they developed intense rectal bleeding and cramps of the extremities that made standing and walking difficult. Suppression of the drug led to resolution of these manifestations.

Conclusion

Although there are not enough studies to determine PVL etiology and no simplified diagnosis criteria, the most difficult point is PVL treatment. According to the literature reviewed, PVL seems to be resistant to many therapy attempts and often has high propensity for dysplasia and/or malignancy progression. Modalities such as surgery, laser ablation, photodynamic therapy, retinoid, radiation and chemotherapy are not effective in reducing relapses and malignant transformation.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgment

We thank Professor Filipe Modolo Siqueira for technical assistance in reviewing histopathological findings and images.

References

Proliferative verrucous leukoplakia: diagnosis, management and current advances